The fibroblast growth factor (FGF) signaling axis is increasingly implicated in tumorigenesis and chemoresistance through discovery of the molecular deregulation (including overexpression and genetic modification) of both ligands and receptors across multiple tumor types. Several small molecule FGF-receptor (FGFR) kinase inhibitors are currently in clinical development.
ligands, additional control is provided by the interaction of heparin and heparin sulphate proteoglycans (HSPGs) which modulate ligand binding to receptor (2) . Cell-and tissue-specific receptor expression patterns provide a final level of control which reflects their differential roles across a variety of tissues and cell lineages.
Aside from their normal physiological roles described above, FGFs and FGFRs are emerging as oncogenes that drive proliferation of a significant proportion of human tumors and which can also mediate resistance to both cytotoxic and targeted agents. Deregulation of FGFR-signaling has been documented in clinical samples of breast (3), multiple myeloma (4), bladder (5) , endometrial (6) , gastric (7) and prostate cancers (8) . The most frequently reported tumor-associated finding is receptor overexpression due to gene amplification or aberrant transcriptional regulation. Consequently, tumor cells acquire enhanced sensitivity to FGF ligands or become activated through spontaneous ligand-independent dimerization (9) (10) (11) (12) (13) . Genetically altered forms of FGFR proteins (e.g. chimeric, truncated, mutated) have also been identified in human tumors, resulting in receptors which are either constitutively active or exhibit altered ligand-dependence (12, 14) . Moreover, receptor activation through gene fusion is exemplified by the discovery of numerous FGFR1-fusion proteins in myeloproliferative disorders (15) (16) (17) .
Finally, FGF2 and FGFR4 have both been associated with protection against etoposide and doxorubicin-induced apoptosis in vitro (18) (19) (20) (21) , whilst increased circulating FGF2 levels show an association with tumor progression following clinical suppression of VEGF-signaling (22, 23) .
Blockade of FGF/FGFR signaling as a therapeutic approach to cancer is gaining momentum with a number of targeted kinase inhibitors currently in development. The most clinically advanced of these agents are mainly mixed kinase inhibitors with dominant anti-KDR pharmacology (brivanib alaninate (24) , dovitinib (11) , BIBF-1120 (25) and SU6668 (26) . As such, their anti-FGFR activity is often relatively weak and thus, we do not believe these agents offer the opportunity to fully test the anti-FGFR hypothesis because of the confounding effects of their other pharmacological mechanisms.
Accordingly, we postulate that there is a need for compounds that are more FGFR-selective, which can be used to more robustly test the FGFR tumordrive hypothesis. In this report, we describe the preclinical profile of AZD4547, a potent and selective FGFR tyrosine kinase inhibitor currently in Phase I clinical studies.
Materials and Methods

AZD4547.
N In vitro cell line proliferation studies. In vitro antiproliferative activity was measured as described previously (27) . Each experiment was carried out at least in triplicate and data presented as geometric means. Murine plasma pharmacokinetic analyses. Plasma samples were extracted by protein precipitation in acetonitrile, followed by LC-MS/MS detection. In short, plasma samples and standards were quenched with acetonitrile and internal standard and centrifuged. Supernatant was diluted 10-fold with deionized water and the samples were analyzed by LC-MS/MS using Masslynx and data processed using Quanlynx software (Waters).
In vitro
Immunohistochemistry. Antigen retrieval was performed on formalin-fixed, paraffin-embedded tissues using a RHS-1 microwave vacuum processor In vivo cardiovascular studies. Blood pressure, heart rate and activity patterns were collected from conscious, unrestrained rats using the commercially available Data Sciences International (DSI) telemetry system using methodology described previously (29) .
Results
AZD4547 is a highly potent inhibitor of FGFR tyrosine kinases 1-3 and
shows selectivity versus a range of additional kinases. AZD4547 potently inhibits the tyrosine kinase activities of recombinant FGFR1,2 and 3 in vitro were assessed by Western blotting and overexpression was confirmed relative to a control cell line (MCF7) with no identified defects in FGFR expression or signaling (Fig. 2) . The ability of AZD4547 to inhibit in vitro proliferation of these lines over a three day period was assessed using a standard metabolism-based proliferation assay. IC 50 values ranged from 18 nM in KG1a cells to 281 nM in KMS11 cells (Table 2) . Notably, MCF7 cell proliferation was unaffected by incubation with AZD4547 up to a concentration of 30 μM. Moreover, AZD4547 was inactive against more than 100 additional tumor cell lines (Supplementary Table S1 ), demonstrating that AZD4547 has potent in vitro antiproliferative activity only against tumor cell lines expressing deregulated FGFRs. Table 2 ). The phosphorylation of FRS2 and PLCγ, downstream markers of FGFR signaling, were also inhibited ( Fig. 3D-E) . Notably, AKT phosphorylation (which has been described to couple often to FGFR signaling) was unaffected by Within 15 minutes of drug administration, the levels of phosphorylated FGFR3 decreased to 40-50% of control levels and inhibition was sustained for at least 6 hours. At the 16 hour timepoint, phosphorylated FGFR3 had returned to control levels (Fig. 5C ). These data confirm good modulation of tumor phospho-FGFR3 levels for at least 6 hours, consistent with the plasma exposure of AZD4547.
To define the mechanism(s) through which AZD4547 elicits KMS11 tumor growth inhibition in vivo, KMS11 tumor-bearing mice were treated with 6.25 mg/kg AZD4547 twice daily for 7 days and tumors processed for immunohistochemical analysis. Tumor sections were stained using antibodies to cleaved caspase 3, Ki67 and CD31, representing markers of cellular apoptosis, proliferation and vascularity, respectively. AZD4547 treatment caused a significant reduction in the percentage of cells staining positive for nuclear Ki67 (Fig. 5D and 5E ). However, despite showing an increase in the AZD4547-treated sections, the difference in cleaved caspase 3 staining between control versus AZD4547-treated tumor sections did not reach statistical significance. Similarly, AZD4547 treatment did not have any significant effect on CD31 positive vessel staining in KMS11 xenografts ( Fig.   5D and 5E), demonstrating that at efficacious dose levels AZD4547 does not exhibit anti-angiogenic effects. In summary, AZD4547 demonstrates doseproportional anti-tumor efficacy in an FGFR3-driven xenograft model, concurrent with pharmacodynamic target modulation, and with evidence of a predominantly antiproliferative mechanism in vivo.
AZD4547 anti-tumor efficacy is not attributable to inhibition of KDRdriven functional effects in vivo. It is well documented that inhibition of
VEGF signaling with agents such as cediranib (KDR inhibitor) can lead to hypertension (29, 33) . Therefore, the effect of AZD4547 on blood pressure was measured in conscious telemetered rats. Two separate oral doses of 10 mg/kg AZD4547 over 24 hours did not lead to any significant changes in blood pressure compared with vehicle-dosed animals ( Fig. 6A represents the diastolic pressure for vehicle control and AZD4547). The free plasma exposure of AZD4547 after dosing at 10 mg/kg in rats is equivalent to the exposure in mouse which results in greater than 60% tumor growth inhibition in the KMS11 model. These data demonstrate that at equivalent efficacious doses, AZD4547 has no significant effect on blood pressure and therefore lacks in vivo anti-KDR activity.
Broad antitumor efficacy in preclinical xenograft models is a feature of agents which act predominantly through anti-angiogenic mechanisms. To examine the breadth of its activity, AZD4547 was assessed in a number of models which have been shown to be sensitive to inhibitors of VEGF signaling, such as cediranib (28) . Mice bearing Calu-6 (lung) tumors were treated chronically with either 3 mg/kg cediranib once-daily or 6.25 mg/kg AZD4547 twice-daily.
Cediranib resulted in significant tumor growth inhibition (64%) which is consistent with previous reports (28) , however AZD4547 lacked efficacy in this model (Fig.6B) . Similarly, dosing of 6.25 mg/kg po bid AZD4547 was also inactive in two additional cediranib-sensitive xenograft models -HCT-15 and LoVo (Table 3) .
Taken together, the telemetry, immunohistochemical and efficacy data suggest that the antitumor effects of AZD4547 are not likely to be attributable to inhibition of KDR activity and are a result of its potent and selective FGFR profile. The in vivo data presented here is consistent with AZD4547 being a predominantly FGFR-selective small molecule inhibitor. Treatment with AZD4547 did not result in the well-characterized blood pressure changes associated with acute KDR inhibition in telemetered rat studies (29, 33 p38 >100000
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*The ability of AZD4547 to inhibit a range of human recombinant kinase activities was tested using ATP concentrations at, or just below, the respective K m . Data represents the mean ± SEM of at least three separate determinations. IC 50 values denoted as "greater than" denote the inability to reach 50% inhibition of maximal activity at the highest tested concentration. 
